M K Walton1, J C Cappelleri2, B Byrom3, J C Goldsack4, S Eremenco5, D Harris6, E Potero7, N Patel8, E Flood8, M Daumer9. 1. Janssen Research and Development, Titusville, NJ, USA. 2. Pfizer Inc, Groton, CT, USA. 3. Signant Health, London, UK. Electronic address: bill.byrom@signanthealth.com. 4. Digital Medicine Society (DiMe), Sarasota, FL, USA. 5. Critical Path Institute, Tucson, AZ, USA. 6. Takeda, Boston, MA, USA. 7. Biogen, Cambridge, MA, USA. 8. AstraZeneca, Gaithersburg, MD, USA. 9. Sylvia Lawry Centre for Multiple Sclerosis Research, Munich, Germany.
Abstract
BACKGROUND: Mobile sensors offer enormous potential for the collection of informative clinical endpoints in clinical trials to support regulatory decision making and product labelling. There are currently no specific guidelines on the information needed to enable regulators to review and accept proposed endpoints derived from mobile sensors for use in drug development trials. OBJECTIVE: The purpose of this working group report is to recommend the structure and content of an evidence dossier intended to support whether a clinical endpoint derived from mobile sensor data is fit-for-purpose for use in regulatory submissions for drug approvals. EVIDENCE DOSSIER: The structure and content of a dossier to provide evidence supporting the use of a sensor-derived clinical endpoint is described. Sections include clinical endpoint definition and positioning, the concept of interest, the context of use, clinical validation and interpretation, study implementation, and analytical validity with sensor performance verification in support of the selected sensor. CONCLUSIONS: In the absence of definitive regulatory guidance, this report provides a considered approach to compiling a comprehensive body of evidence to justify acceptance of mobile sensors for support of new drug applications.
BACKGROUND: Mobile sensors offer enormous potential for the collection of informative clinical endpoints in clinical trials to support regulatory decision making and product labelling. There are currently no specific guidelines on the information needed to enable regulators to review and accept proposed endpoints derived from mobile sensors for use in drug development trials. OBJECTIVE: The purpose of this working group report is to recommend the structure and content of an evidence dossier intended to support whether a clinical endpoint derived from mobile sensor data is fit-for-purpose for use in regulatory submissions for drug approvals. EVIDENCE DOSSIER: The structure and content of a dossier to provide evidence supporting the use of a sensor-derived clinical endpoint is described. Sections include clinical endpoint definition and positioning, the concept of interest, the context of use, clinical validation and interpretation, study implementation, and analytical validity with sensor performance verification in support of the selected sensor. CONCLUSIONS: In the absence of definitive regulatory guidance, this report provides a considered approach to compiling a comprehensive body of evidence to justify acceptance of mobile sensors for support of new drug applications.
Authors: Lynn Rochester; Claudia Mazzà; Arne Mueller; Brian Caulfield; Marie McCarthy; Clemens Becker; Ram Miller; Paolo Piraino; Marco Viceconti; Wilhelmus P Dartee; Judith Garcia-Aymerich; Aida A Aydemir; Beatrix Vereijken; Valdo Arnera; Nadir Ammour; Michael Jackson; Tilo Hache; Ronenn Roubenoff Journal: Digit Biomark Date: 2020-11-26
Authors: Diane Stephenson; Robert Alexander; Varun Aggarwal; Reham Badawy; Lisa Bain; Roopal Bhatnagar; Bastiaan R Bloem; Babak Boroojerdi; Jackson Burton; Jesse M Cedarbaum; Josh Cosman; David T Dexter; Marissa Dockendorf; E Ray Dorsey; Ariel V Dowling; Luc J W Evers; Katherine Fisher; Mark Frasier; Luis Garcia-Gancedo; Jennifer C Goldsack; Derek Hill; Janice Hitchcock; Michele T Hu; Michael P Lawton; Susan J Lee; Michael Lindemann; Ken Marek; Nitin Mehrotra; Marjan J Meinders; Michael Minchik; Lauren Oliva; Klaus Romero; George Roussos; Robert Rubens; Sakshi Sadar; Joseph Scheeren; Eiichi Sengoku; Tanya Simuni; Glenn Stebbins; Kirsten I Taylor; Beatrice Yang; Neta Zach Journal: Digit Biomark Date: 2020-11-26
Authors: Iredia M Olaye; Mia P Belovsky; Lauren Bataille; Royce Cheng; Ali Ciger; Karen L Fortuna; Elena S Izmailova; Debbe McCall; Christopher J Miller; Willie Muehlhausen; Carrie A Northcott; Isaac R Rodriguez-Chavez; Abhishek Pratap; Benjamin Vandendriessche; Yaara Zisman-Ilani; Jessie P Bakker Journal: J Med Internet Res Date: 2022-04-14 Impact factor: 5.428
Authors: Johannes Lorscheider; Yvonne Naegelin; Tim Woelfle; Silvan Pless; Oscar Reyes; Andrea Wiencierz; Anthony Feinstein; Pasquale Calabrese; Konstantin Gugleta; Ludwig Kappos Journal: J Neurol Date: 2022-08-30 Impact factor: 6.682
Authors: Alan Godfrey; Benjamin Vandendriessche; Jessie P Bakker; Cheryl Fitzer-Attas; Ninad Gujar; Matthew Hobbs; Qi Liu; Carrie A Northcott; Virginia Parks; William A Wood; Vadim Zipunnikov; John A Wagner; Elena S Izmailova Journal: Clin Transl Sci Date: 2020-08-25 Impact factor: 4.689